FR EA

Extract to table

Pull the structured facts out of a document: parties, dates, amounts, obligations.

Extract to table / series-a-preferred-consent.docx
series-a-preferred-consent.docx · 1013-00003

Parties

Delaware General Corp
Genome Dx Therapeutics Inc
Whitepine Ventures Management LLC

Dates

March 22, 2021
September 10, 2025
March 12, 2027

Amounts

$0.0001
$5,000,000
$8,000,000
$20,000,000

Obligations

The aggregate principal amount of all Notes issued under the Note Purchase Agreement shall not exceed $8,000,000
This Written Consent shall be effective as of September 10, 2025 (the date first written above)
Prompt notice of the taking of the corporate action set forth herein shall be given to those holders of Series A Preferred Stock that have not consented hereto in writing, to the extent required by Section 228(e) of the DGCL
pdf)), each of which shall be deemed an original and all of which, taken together, shall constitute one and the same instrument
Delivery of an executed counterpart of this Written Consent by facsimile or by electronic transmission shall be equally effective as delivery of a manually executed counterpart hereof
Nothing contained herein shall be deemed to amend, modify, supplement, restate, or waive any other provision of the Series A IRA, and all such provisions shall remain in full force and effect in accordance with their respective terms